Search

Outcomes of renal cancer surgery on renal function and mortality on those with and without CKD

In urology we are encountering an ageing and more comorbid population, including a group of patients with chronic kidney disease (CKD). In this retrospective study, a group from the Cleveland Clinic present the extended follow-up of patients with and without...

Is TRUS and biopsy obsolete as a diagnostic test for prostate cancer: refining the perineal biopsy technique?

Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...

Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...

The future of bladder preservation for muscle-invasive bladder cancer

Localised muscle-invasive bladder cancer (MIBC) has historically been treated with radical cystectomy (RC), but bladder preservation therapy (BPT) has emerged as a credible and increasingly refined alternative. Early work by Herr in the 1980s demonstrated that radical transurethral resection of...